VANCOUVER, BC, Dec. 15,
2023 /PRNewswire/ - Numinus Wellness
Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF),
a mental health care company advancing traditional and innovative
behavioral health treatments with a focus on safe, evidence-based
psychedelic-assisted therapies, is proud to announce that its
research site, Cedar Clinical Research (CCR), has been chosen as
one of multiple sites for Beckley Psytech's cutting-edge Phase
2b clinical trial for Treatment
Resistant Depression (TRD).
The study aims to evaluate the efficacy and safety of different
doses of Beckley Psytech's proprietary intranasal formulation of
synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) – known as
BPL-003 – as a potential therapy for TRD. It follows Beckley
Psytech's receipt of the U.S. Food and Drug Administration's (FDA)
first-ever Investigational New Drug (IND) approval for a Phase
2b study of a short-acting
psychedelic compound in February this year. CCR's selection as a
clinical research site for this trial further establishes it as a
leader in psychedelic clinical research and builds upon its
commitment to forging collaborations that explore new mental health
solutions.
"We are excited to be supporting Beckley Psytech in their
clinical trial endeavors. Such partnerships are not just a
reflection of CCR's dedication to advancing the frontiers of mental
health research; they also spotlight our capabilities and the
world-class infrastructure that positions us as a sought-after
clinical research hub," stated Dr. Paul
Thielking, Chief Science Officer at Numinus. "Our
collaboration with Beckley Psytech underscores a shared vision and
commitment to bringing the highest research standards to
psychedelic clinical trials. With each ground-breaking project, we
further cement our global standing, always driven by innovation,
integrity, and excellence."
Numinus and CCR's collaboration with Beckley Psytech reflects a
unified drive for innovation in psychedelic-assisted therapies. As
leaders in mental health solutions, they eagerly anticipate the
transformative insights this Phase 2b
trial will offer to the broader medical community.
Numinus and CCR remain at the forefront of advancing
psychedelic-assisted therapies, underscoring a deep-seated
commitment to research that paves the way for comprehensive
healing. Click this link at Beckley Psytech to learn more about the
study.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
About Beckley Psytech
Beckley Psytech Ltd is a private, clinical-stage biotechnology
company dedicated to improving the lives of people suffering from
neuropsychiatric disorders by transforming psychedelics into
effective and licensed medicines. Founded in 2019 and underpinned
by more than two decades of pioneering scientific research from the
Beckley Foundation, Beckley Psytech combines world-leading
psychedelic science with extensive drug development expertise in
order to optimize patient outcomes, improve treatment opportunities
and ease the burden neuropsychiatric conditions have on
individuals, healthcare systems and society.
Forward-looking statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including but not limited to the
challenges and uncertainties inherent in product and/or treatment
development and in the psychedelics industry generally, availably
of suitable subjects, the uncertainties of clinical success,
possibility of adverse events, ability to meet project timelines
and/or protocol requirements, and the risks set forth in the
Company's annual information form dated November 29, 2023, and available on SEDAR+ at
www.sedarplus.com. Forward-looking statements are based on
estimates and opinions of management at the date the statements are
made. The Company does not undertake any obligation to update
forward-looking statements even if circumstances or management's
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cedar-clinical-research-selected-as-clinical-research-site-for-beckley-psytechs-phase-2b-study-302016865.html
SOURCE Numinus Wellness Inc.